Considering the relevance of ALK activity and mTOR signaling for the survival and proliferation of ALK+ tumor cells, we decided to investigate the effects of the simultaneous targeting of ALK and mTOR pathways in ALK+ ALCL, in order to increase the antitumor efficacy of the single agents and to prevent the selection of resistant clones. This evidence concerns the gene ALK and anaplastic large cell lymphoma.